{
    "clinical_study": {
        "@rank": "21535", 
        "acronym": "Pin1", 
        "arm_group": {
            "arm_group_label": "D. pteronyssinus allergens", 
            "arm_group_type": "Experimental", 
            "description": "Single arm study exploring the role of Pin-1 enzyme in development of Asthma. Bronchoscopy before and 48 hours after installation of D. pteronyssinus allergens into the lung segments"
        }, 
        "brief_summary": {
            "textblock": "Pin1 is activated in asthmatic airways, increasing cytokine mRNA stability and eosinophil\n      survival. This study is designed to test whether the Pin1 enzyme regulates TLR/IL-1R signal\n      pathways in multiple cells in asthma."
        }, 
        "brief_title": "Role of the Isomerase Pin-1 in the Development and Treatment of Asthma", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "detailed_description": {
            "textblock": "The investigators will test their hypothesis that Pin1 regulates TLR/IL-1R signaling\n      pathways in asthma by examining Pin1 and related pathway activation in BAL-derived\n      eosinophils after house dust mite allergen challenge.  The investigators will perform\n      segmental allergen challenge. BAL and lung biopsy of the allergen-challenged segments will\n      be performed 48 hr later and activation of Pin1 and related pathways will be examined."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Subjects 18-55 years of age, diagnosed with asthma for at least 1 year;\n\n          -  And FEV1 > 70% predicted on only short acting beta agonists e.g albuterol\n\n          -  And methacholine PC20 < 8 mg/ml\n\n          -  Positive skin prick test to Dermatophagoides pteronyssinus(DerP)\n\n          -  No prior history of intubation for asthma\n\n          -  No use of inhaled corticosteroids for 1 month prior to entry\n\n        Exclusion criteria:\n\n          -  Current smoking or smoking history of greater than 10 pack-years\n\n          -  Any other clinically important comorbidity determined by the principal investigator\n             to affect subject safety, including uncontrolled diabetes, uncontrolled coronary\n             artery disease, acute or chronic renal failure, and uncontrolled hypertension that\n             would increase the risk of significant adverse events during bronchoscopy,\n\n          -  Worsening of asthma symptoms requiring treatment with steroids within 4 weeks of\n             screening\n\n          -  Respiratory infection within four weeks\n\n          -  Women of child-bearing potential, defined as all women physiologically capable of\n             becoming pregnant or who are currently pregnant or lactating.\n\n        Unless they:\n\n          -  Are women whose career, lifestyle, or sexual orientation precludes intercourse with a\n             male partner\n\n          -  Are women whose partners have been sterilized by vasectomy or other means\n\n          -  Use one acceptable birth control method. Adequate barrier methods of contraception\n             include: diaphragm, condom (by the partner), intrauterine device (copper or\n             hormonal), sponge or spermicide. Hormonal contraceptives include any marketed\n             contraceptive agent that includes an estrogen and/or a progestational agent.\n\n          -  Pre-existing lung disease other than asthma\n\n          -  History of coagulation disorders or abnormal PT/PTT testing at screening\n\n          -  History of immunodeficiency diseases, including HIV\n\n          -  A disability that may prevent the patient from completing all study requirements\n\n          -  Use of other investigational drugs at the time of enrollment, or within 30 days or 5\n             half-lives of enrollment, whichever is longer\n\n          -  History of malignancy of any organ system (other than localized basal cell carcinoma\n             of the skin), treated or untreated, within the past 5 years, regardless of whether\n             there is evidence of local recurrence or metastases.\n\n          -  Diagnosis of Hepatitis B or C.\n\n          -  History of alcohol abuse (as determined by the principal investigator) within 6\n             months of screening.\n\n          -  History of illicit drug abuse (as determined by the principal investigator) within 6\n             months of screening."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01691612", 
            "org_study_id": "2012P001029"
        }, 
        "intervention": {
            "arm_group_label": "D. pteronyssinus allergens", 
            "description": "We will perform bronchoscopy and segmental allergen challenges. Subjects will undergo bronchoscopy with segmental installation of 5 ml of D. pteronyssinus (DerP). BAL and lung biopsy of the allergen-challenged segments will be performed 48 hr later", 
            "intervention_name": "installation of D. pteronyssinus allergens", 
            "intervention_type": "Biological", 
            "other_name": "D. pteronyssinus allergens exposure"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Role of Pin-1 enzyme in Asthma", 
        "lastchanged_date": "August 5, 2013", 
        "location": {
            "contact": {
                "email": "acrosby-thompson@partners.org", 
                "last_name": "Allison Crosby-Thompson", 
                "phone": "617-525-8034"
            }, 
            "contact_backup": {
                "email": "kfnelson@partners.org", 
                "last_name": "Kyle F Nelson", 
                "phone": "617-732-8630"
            }, 
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02115"
                }, 
                "name": "Asthma Research Center"
            }, 
            "investigator": [
                {
                    "last_name": "Elliot Israel, M.D", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Shamsah Kazani, M.D., MMSc", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Role of the Isomerase Pin-1 in the Development and Treatment of Asthma", 
        "overall_contact": {
            "email": "acrosby-thompson@partners.org", 
            "last_name": "Allison Crosby-Thompson, M.S.", 
            "phone": "617-525-8034"
        }, 
        "overall_official": [
            {
                "affiliation": "Beth Israel Deaconess Medical Center", 
                "last_name": "Kun P Lu, M.D., PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Brigham and Womens Hospital", 
                "last_name": "Elliot Israel, M.D", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "We will measure Pin1 activity in BAL-derived eosinophils after House Dust Mite (HDM) allergen challenge.", 
            "measure": "Pin1 enzyme activation in BAL-derived eosinophils", 
            "safety_issue": "No", 
            "time_frame": "48 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01691612"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Brigham and Women's Hospital", 
            "investigator_full_name": "Elliot Israel, MD", 
            "investigator_title": "Physician", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Brigham and Women's Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Brigham and Women's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}